{"id":"W4282967960","doi":"10.1158/1538-7445.am2022-ct168","title":"Abstract CT168: Randomized phase 2 trial of sunitinib or cediranib in alveolar soft part sarcoma","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Sunitinib; Clinical endpoint; Randomized controlled trial; Alveolar soft part sarcoma; Surgery; Tolerability; Phases of clinical research; Oncology; Gastroenterology; Clinical trial; Cancer; Soft tissue; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001868214,0.002264976,0.00263423,0.0004979572,0.0004887718,0.0009530136,0.0009829622,0.001490931,0.0131254],"category_scores_gemma":[0.001589282,0.0006990723,0.001207776,0.0004130591,0.0009884415,0.001186261,0.0004257472,0.003093881,0.001790474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001156487,"about_ca_system_score_gemma":0.002323796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001186946,"about_ca_topic_score_gemma":0.003355035,"domain_scores_codex":[0.9995241,0.0002632898,0.00002969012,0.00008482218,0.00003866554,0.00005938203],"domain_scores_gemma":[0.9992118,0.0001336778,0.0001775568,0.00004906502,0.00005622243,0.0003716432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9685113,0.007385639,0.0006569851,0.0005716456,0.0004519804,0.00008289923,0.00003936987,0.000495703,0.005391134,0.0001476641,0.002787613,0.01347798],"study_design_scores_gemma":[0.9216108,0.07560191,0.000877766,0.00002207208,0.0001556603,0.00006932052,0.00001191617,0.0003426574,0.000339208,0.0001201074,0.0008375655,0.00001084041],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764745,0.003328256,0.0008336713,0.00136426,0.0007434667,0.009667156,0.003124262,0.0002844133,0.004180055],"genre_scores_gemma":[0.9679397,0.002028841,0.00299175,0.001802663,0.0006752801,0.01227884,0.004004439,0.00004951617,0.008228988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0131254,"threshold_uncertainty_score":0.04390877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1807471772690715,"score_gpt":0.4749018091824065,"score_spread":0.294154631913335,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}